Press Releases Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
48.78 ^USD	-2.62%		-10.56%	+118.94%

May. 01	Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target	MT
Apr. 11	Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024	May. 10	AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	AQ
Praxis Precision Medicines : April 2024 Corporate Presentation	Apr. 23	PU
PRAXIS PRECISION MEDICINES TO PRESENT ON ULIXACALTAMIDE AT THE AMERICAN ACADEMY OF NEUROLOGY 2024 ANNUAL MEETING	Apr. 15	AQ
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting	Apr. 12	AQ
Praxis Precision Medicines to Participate in Upcoming April Conferences	Apr. 05	AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 02	AQ
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering	Mar. 28	AQ
Praxis Precision Medicines, Inc. Announces Proposed Public Offering	Mar. 27	AQ
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients	Mar. 26	AQ
Praxis Precision Medicines to Host PRAX-628 Program Update	Mar. 25	AQ
Praxis Precision Medicines : March 2024 Corporate Presentation	Mar. 05	PU
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 05	AQ
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference	Mar. 01	AQ
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 02	AQ
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering	Jan. 11	AQ
Praxis Precision Medicines, Inc. Announces Proposed Public Offering	Jan. 10	AQ
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio	Jan. 08	AQ
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China	Jan. 05	AQ
Praxis Precision Medicines : UNAUDITED SELECTED FINANCIAL DATA (Amounts in thousands, except share and per share data) Reverse Stock Split - Form 8-K	Dec. 01	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Press Releases

Filters